Discovering What Drives Disease
Identifying a promising drug target is not the same as identifying the right target.
Many discovery approaches begin with existing scientific hypotheses or statistical associations. Intellomx takes a different approach.
Our AI interrogates human biological data directly, using causal network modelling and swarm intelligence to uncover disease drivers that conventional approaches may overlook.
We discover new biology—not simply new interpretations of existing research.
Science Applied in Practice
Intellomx has undertaken pharmaceutical target discovery collaborations with Johnson & Johnson in haematological and lung cancers.
Our technology has also been applied across oncology, inflammatory, metabolic, neurological and infectious diseases.
These programmes demonstrate how biology-led AI can create actionable opportunities for therapeutic and diagnostic discovery.
Work With Intellomx
We offer flexible commercial relationships to suit different discovery objectives.
Focused Discovery Projects — Apply our platform to a specific disease, target or portfolio challenge.
Strategic Co-development — Collaborate to discover and develop new therapeutic opportunities.
Asset Licensing — Access internally originated programmes and proprietary discoveries.
Whether you are seeking novel targets, evaluating an existing programme or exploring new drug candidates, we welcome an initial scientific discussion.
From Disease Biology to Drug Candidates
Our integrated I³ platform supports four critical stages of early discovery:
Discover — Reveal causal disease pathways and previously unrecognised therapeutic targets.
Prioritise — Rank targets by biological influence, druggability and potential translational relevance.
De-risk — Use computational Digital Twin models to investigate potential off-target and organ-specific safety liabilities.
Develop — Connect prioritised targets with candidate molecules and biomarker strategies for experimental validation.